Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
X4 Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
11/29/21
11/29
04:55
11/29/21
04:55
XFOR

X4 Pharmaceuticals

$4.54 /

-0.16 (-3.40%)

Virtual Meeting to be…

Virtual Meeting to be held on November 29 hosted by Oppenheimer.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$4.54 /

-0.16 (-3.40%)

XFOR X4 Pharmaceuticals
$4.54 /

-0.16 (-3.40%)

10/19/21 Roth Capital
X4's new hires should be viewed as derisking for Mavorixafor outlook, says Roth
06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$4.54 /

-0.16 (-3.40%)

Over a week ago
Conference/Events
X4 Pharmaceuticals management to meet virtually with Oppenheimer » 12:46
11/18/21
11/18
12:46
11/18/21
12:46
XFOR

X4 Pharmaceuticals

$4.92 /

+0.14 (+2.93%)

Virtual Meeting to be…

Virtual Meeting to be held on November 29 hosted by Oppenheimer.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$4.92 /

+0.14 (+2.93%)

XFOR X4 Pharmaceuticals
$4.92 /

+0.14 (+2.93%)

10/19/21 Roth Capital
X4's new hires should be viewed as derisking for Mavorixafor outlook, says Roth
06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$4.92 /

+0.14 (+2.93%)

Hot Stocks
X4 Pharmaceuticals announces seven presentations at ASH meeting » 09:27
11/04/21
11/04
09:27
11/04/21
09:27
XFOR

X4 Pharmaceuticals

$5.60 /

+0.25 (+4.67%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced a summary of the data contained within the seven abstracts submitted and accepted for presentation and/or publication at the 63rd American Society of Hematology, ASH, Annual Meeting. WHIM syndrome data: Mavorixafor continues to show durable increases in neutrophils and lymphocytes, sustained improvements in infections and warts, and good tolerability in the ongoing Phase 2 open-label extension trial in WHIM syndrome. Patient interviews revealed that study participants experienced good tolerability and beneficial treatment effects when dosed with mavorixafor. The company's global Phase 3 clinical trial in WHIM syndrome is the first double-blind, placebo-controlled, randomized trial in this patient population and the only one exploring an oral therapy. All enrolled patients had severe neutropenia and more than half are pediatric patients, illustrative of the severity and early onset of the disease. Top-line data from the trial are expected in the fourth quarter of 2022. Chronic neutropenia and other indications data: Mavorixafor alone or in combination with other therapies is the first oral treatment to acutely and chronically increase total peripheral white blood cells 1.5- to 3-fold across all disease populations examined. Further, mavorixafor's ability to increase circulating WBCs across various disease states and in healthy individuals supports its potential utility in the treatment of patients with immunodeficiency, regardless of the presence or absence of CXCR4 mutations. A Phase 1b trial in chronic neutropenia populations is ongoing; initial data from this trial are expected to be presented in an ASH poster presentation and at the Investor Day on December 16. Waldenstrom's macroglobulinemia data: Additional preliminary clinical data are presented from the ongoing Phase 1b dose-escalation trial assessing the tolerability and efficacy, including clinical response rates, of mavorixafor in combination with ibrutinib in diagnosed WM patients with both MYD88 and CXCR4 mutations. As of the abstract cutoff date of June 15, 2021, the overall response rate for evaluable patients was 100%, with 4 of 8 patients achieving a major response and 1 of 8 patients achieving very good partial response. Additional clinical data are expected to be presented in an ASH poster presentation and at the Investor Day on December 16.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

10/19/21 Roth Capital
X4's new hires should be viewed as derisking for Mavorixafor outlook, says Roth
06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

Hot Stocks
X4 Pharmaceuticals continues to expect cash to fund operations into Q4 2022 » 09:21
11/04/21
11/04
09:21
11/04/21
09:21
XFOR

X4 Pharmaceuticals

$5.60 /

+0.25 (+4.67%)

X4 had $77.7M in cash,…

X4 had $77.7M in cash, cash equivalents, and restricted cash as of September 30, 2021.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

10/19/21 Roth Capital
X4's new hires should be viewed as derisking for Mavorixafor outlook, says Roth
06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

Earnings
X4 Pharmaceuticals reports Q3 EPS (76c), consensus (72c) » 09:21
11/04/21
11/04
09:21
11/04/21
09:21
XFOR

X4 Pharmaceuticals

$5.60 /

+0.25 (+4.67%)

"This has been an…

"This has been an amazing quarter of progress for all of us at X4, as we completed enrollment in the Phase 3 trial of mavorixafor in its first indication of WHIM syndrome and are now looking ahead to sharing a broad array of clinical and scientific data in the fourth quarter that further support the potential of mavorixafor across multiple additional therapeutic areas," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4. "As we continue to expand our pre-commercial activities for WHIM in anticipation of top-line data late next year, we are also working to build out our pipeline - further advancing clinical trials of mavorixafor in neutropenia and rare oncology indications, while also advancing our pre-clinical programs towards the clinic."

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

10/19/21 Roth Capital
X4's new hires should be viewed as derisking for Mavorixafor outlook, says Roth
06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.60 /

+0.25 (+4.67%)

Over a month ago
Recommendations
X4's new hires should be viewed as derisking for Mavorixafor outlook, says Roth » 14:43
10/19/21
10/19
14:43
10/19/21
14:43
XFOR

X4 Pharmaceuticals

$5.01 /

-0.075 (-1.47%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah reiterated a Buy rating and $27 price target on X4 Pharmaceuticals after the company announced the appointment of Francoise de Craecker to its board and the appointment of Karolyn Park as VP of U.S. Commercial. The analyst said that, with Mavorixafor's commercial outlook being the major overhang for the stock, these two "strong" hires should be viewed as derisking for Mavorixafor's commercial outlook, ahead of the Phase 3 WHIM readout during 4Q22.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.01 /

-0.075 (-1.47%)

XFOR X4 Pharmaceuticals
$5.01 /

-0.075 (-1.47%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.01 /

-0.075 (-1.47%)

XFOR X4 Pharmaceuticals
$5.01 /

-0.075 (-1.47%)

Hot Stocks
X4 Pharmaceuticals appoints Francoise de Craecker to board of directors » 08:16
10/19/21
10/19
08:16
10/19/21
08:16
XFOR

X4 Pharmaceuticals

$5.11 /

-0.11 (-2.11%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced the appointment of Francoise de Craecker to the company's Board of Directors and the recent hiring of Karolyn Park to the newly created role of Vice President, U.S. Commercial, significantly strengthening the company's depth and breadth of commercial leadership experience. Ms. de Craecker's appointment expands the X4 Board of Directors to nine members. Ms. de Craecker currently serves as an Independent Director of the French biopharmaceutical company GenSight. Previously, she served as General Manager Europe, Middle East, and Africa at AveXis Europe. Ms. Park joined X4 in September 2021 as Vice President, U.S. Commercial, bringing nearly 20 years of experience in life science marketing and commercial planning, development, and execution. Previous to X4, she served in multiple roles at Takeda Pharmaceuticals, including Senior Director, U.S. Hematology Portfolio Strategy and Director, U.S. Trintellix Strategy & HCP Marketing Lead.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

Conference/Events
X4 Pharmaceuticals management to meet virtually with B. Riley » 04:55
10/19/21
10/19
04:55
10/19/21
04:55
XFOR

X4 Pharmaceuticals

$5.11 /

-0.11 (-2.11%)

Virtual Meeting to be…

Virtual Meeting to be held on October 19 hosted by B. Riley.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

XFOR X4 Pharmaceuticals
$5.11 /

-0.11 (-2.11%)

Conference/Events
X4 Pharmaceuticals management to meet virtually with B. Riley » 14:29
10/13/21
10/13
14:29
10/13/21
14:29
XFOR

X4 Pharmaceuticals

$5.44 /

+0.04 (+0.74%)

Virtual Meeting to be…

Virtual Meeting to be held on October 19 hosted by B. Riley.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.44 /

+0.04 (+0.74%)

XFOR X4 Pharmaceuticals
$5.44 /

+0.04 (+0.74%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.44 /

+0.04 (+0.74%)

XFOR X4 Pharmaceuticals
$5.44 /

+0.04 (+0.74%)

Hot Stocks
X4 Pharmaceuticals completes enrollment in Phase 3 mavorixafor trial » 08:30
10/04/21
10/04
08:30
10/04/21
08:30
XFOR

X4 Pharmaceuticals

$5.16 /

-0.18 (-3.37%)

X4 Pharmaceuticals…

X4 Pharmaceuticals announced that it has completed enrollment in the ongoing pivotal Phase 3 clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed WHIM syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene. Thirty-one adult and pediatric patients have enrolled in the 4WHIM trial, which compares a once-daily, oral dose of mavorixafor to placebo across primary and secondary endpoints that include clinically relevant counts of neutrophils and lymphocytes, the frequency and severity of both infections and warts, as well as certain quality of life measurements. The trial was originally designed to enroll 18-28 patients.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$5.16 /

-0.18 (-3.37%)

XFOR X4 Pharmaceuticals
$5.16 /

-0.18 (-3.37%)

06/11/21 Roth Capital
X4 Pharmaceuticals price target raised to $27 from $23 at Roth Capital
12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
XFOR X4 Pharmaceuticals
$5.16 /

-0.18 (-3.37%)

XFOR X4 Pharmaceuticals
$5.16 /

-0.18 (-3.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.